Related Experiment Videos
Implications for neuroprotective treatments
1GKT School of Biomedical Sciences, Henriette Raphael House, Guy's Campus, London SE1 1UL, UK. brian.meldrum@kcl.ac.uk
Abstract:
Pharmacological neuroprotection against the consequences of seizures can be considered as primary neuroprotection where the object is to diminish the initial insult by suppressing the seizure activity or diminishing the associated ionic fluxes (of which the entry of Na+ and Ca2+ are the most significant), and secondary neuroprotection where the target is some later event in the chain linking ionic changes to altered brain morphology or function. Thus primary neuroprotection is provided by antiepileptic drugs and compounds acting on voltage-sensitive Na+ and Ca2+ channels or on glutamate receptors (NMDA, AMPA/KA or Group I metabotropic). Secondary neuroprotection may be a result of acting on the cascade leading to necrosis (e.g. free radical scavengers, NitricOxide synthase inhibitors, CycloOxygenase-2 inhibitors) or the cascades leading to apoptosis (e.g. MAP-kinase inhibitors, caspase-3 inhibitors). Other approaches may diminish the long-term morphological and functional effects of seizures (e.g. neurotrophin-related therapies). We need improved preclinical tests for identifying novel compounds with potential for providing secondary neuroprotection and antiepileptogenesis. Clinical trials of neuroprotective agents in chronic epilepsy in adults pose major practical difficulties but the severe childhood epilepsies provide opportunities for aggressive testing of novel compounds.
Insights
Pharmacological neuroprotection aims to reduce seizure damage by targeting initial insults or later cellular events. Improved preclinical tests are crucial for developing new neuroprotective and antiepileptogenic compounds, especially for childhood epilepsies.
Area of Science:
- Neuroscience
- Pharmacology
- Epilepsy Research
Background:
- Seizures can cause significant brain damage through initial insults and subsequent cellular events.
- Pharmacological neuroprotection strategies target either the acute seizure activity (primary) or the downstream consequences (secondary).
Purpose of the Study:
- To differentiate between primary and secondary neuroprotection mechanisms in seizure management.
- To highlight the need for improved preclinical models for identifying novel neuroprotective and antiepileptogenic agents.
- To identify opportunities for testing neuroprotective compounds in severe childhood epilepsies.
Main Methods:
- Review of pharmacological targets for primary neuroprotection, including ion channels (Na+, Ca2+) and glutamate receptors (NMDA, AMPA/KA).
- Analysis of secondary neuroprotection pathways targeting necrosis (free radical scavengers, NOS inhibitors, COX-2 inhibitors) and apoptosis (MAP-kinase, caspase-3 inhibitors).
- Consideration of neurotrophin-related therapies for long-term morphological and functional effects.
Main Results:
- Primary neuroprotection involves suppressing seizure activity and managing ionic fluxes.
- Secondary neuroprotection targets cellular cascades (necrosis, apoptosis) or long-term effects following seizures.
- Current preclinical tests require enhancement for effective identification of novel compounds.
Conclusions:
- Developing effective neuroprotective and antiepileptogenic therapies requires a deeper understanding of both primary and secondary mechanisms.
- Severe childhood epilepsies offer a critical window for testing novel neuroprotective agents.
- Improved preclinical models are essential for advancing the field of neuroprotection in epilepsy.